Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds –– Expected to Fund Completion of Phase 3 ENSURE ...
Immunic, Inc. , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the pricing of a private placement ...
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the presentation of ...
In a bid to treat blindness, Life Biosciences will try out potent cellular reprogramming technology on volunteers. When Elon Musk was at Davos last week, an interviewer asked him if he thought aging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results